

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

CHEMGENEX PHARMACEUTICALS LTD

ABN 79 000 248 304

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	UNLISTED ESOP OPTIONS ("ESOP OPTIONS").
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	10,956,281 ESOP OPTIONS ISSUED 600,000 ESOP OPTIONS LAPSED
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	10,956,281 ESOP OPTIONS WITH A \$0.475 EXERCISE PRICE ISSUED TO NEW AND EXISTING EMPLOYEES. ESOP OPTIONS HAVE VARIOUS VESTING DATES RANGING FROM 31 MARCH 2011 TO 30 NOVEMBER 2014 AND ARE SUBJECT TO PERFORMANCE CRITERION. ESOP OPTIONS EXPIRE ON EITHER 30 NOVEMBER 2014 OR 30 NOVEMBER 2015. 600,000 ESOP OPTIONS WITH A \$0.78 EXERCISE PRICE LAPSED.

+ See chapter 19 for defined terms.

4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?	ESOP OPTIONS HAVE NO ENTITLEMENTS UNTIL EXERCISED AND CONVERTED TO ORDINARY SHARES.						
	<p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 							
5	Issue price or consideration	NIL						
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	GRANTING OF ESOP OPTIONS AS PART OF EMPLOYEE REMUNERATION TO ALIGN REMUNERATION WITH SHAREHOLDER VALUE						
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	N/A						
8	Number and +class of all +securities quoted on ASX (<i>including</i> the securities in clause 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="703 1496 975 1529">Number</th> <th data-bbox="983 1496 1369 1529">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="703 1536 975 1570">283,348,870</td> <td data-bbox="983 1536 1369 1570">ORD SHARES</td> </tr> <tr> <td data-bbox="703 1637 975 1671">10,949,328</td> <td data-bbox="983 1637 1369 1733">CXSOA OPTIONS EXPIRING 8 FEB 2012, EXERCISABLE AT \$0.68</td> </tr> </tbody> </table>	Number	+Class	283,348,870	ORD SHARES	10,949,328	CXSOA OPTIONS EXPIRING 8 FEB 2012, EXERCISABLE AT \$0.68
Number	+Class							
283,348,870	ORD SHARES							
10,949,328	CXSOA OPTIONS EXPIRING 8 FEB 2012, EXERCISABLE AT \$0.68							

	Number	+Class
9	28,814,781	ESOP OPTIONS (INCLUDING AGM APPROVED OPTIONS) EXPIRING AT VARIOUS DATES AND EXERCISABLE AT VARIOUS PRICES
	10,000,000	CONVERTIBLE NOTES CONVERTIBLE AT A\$0.50 PER SHARE
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	
	N/A	

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	+Class of +securities to which the offer relates	N/A
15	+Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A

+ See chapter 19 for defined terms.

- 19 Closing date for receipt of acceptances or renunciations of
- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺security holders
- 25 If the issue is contingent on ⁺security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do ⁺security holders sell their entitlements *in full* through a broker?
- 31 How do ⁺security holders sell

part of their entitlements through a broker and accept for the balance?

32 How do +security holders dispose of their entitlements (except by sale through a broker)?

N/A

33 +Despatch date

N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents N/A

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

+ See chapter 19 for defined terms.

39 Class of +securities for which quotation is sought

--

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

--

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

--

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)		

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.

- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Date: 23 December 2010

Print name: James Campbell, Company Secretary

== == == == ==

+ See chapter 19 for defined terms.